Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Jessa Hospital
Modality
Small molecule
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04212403CT.gov Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urinary Tract Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Ofloxacin (this asset) | Jessa Hospital | N/A | D · 30 |
| Normal Human Serum Albumin | EASL - CLIF Consortium | P4 | BB |
| Cranberry | Rennes University Hospital | P3 | B |
| Allocetra-Ots | Enlivex Therapeutics Ltd. | P2 | CCC |
| Cotrimoxazole | Indonesia University | P2 | CC |
| Gentamicin | Medstar Health Research Institute | Early P1 | C |
| Lactobacillus Rhamnosus Gg | Medstar Health Research Institute | Early P1 | C |
| Replens | Alta Bates Summit Medical Center | Early P1 | C |
| Coconut Oil | Alta Bates Summit Medical Center | Early P1 | C |
+1 more in the Urinary Tract Infection cohort
Other indications for L-Ofloxacin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic Syndrome | — | P3 | BB · 68 |
| Cholangitis | — | P4 | BB · 65 |
| Acute Leukemia Of Ambiguous Lineage | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Ofloxacin in Urinary Tract Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-ofloxacin-urinary-tract-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →